Journal Mobile Options
Table of Contents
Vol. 52, No. 2, 2005
Issue release date: August 2005
Neuropsychobiology 2005;52:55–61

Promoter Polymorphisms of the Interferon-α Receptor Gene and Development of Interferon-Induced Depressive Symptoms in Patients with Chronic Hepatitis C: Preliminary Findings

Yoshida K. · Alagbe O. · Wang X. · Woolwine B. · Thornbury M. · Raison C.L. · Miller A.H.
aDepartment of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, Ga., USA; bDepartment of Psychiatry, Akita University School of Medicine, Akita, Japan

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Background: Interferon (IFN)-α treatment frequently induces depression, which can impair quality of life and reduce treatment adherence. Defining relevant risk factors for IFN-α-induced depression is essential for designing preventative treatment strategies. Objective: The purpose of the present study was to determine whether promoter polymorphisms of –408C/T, –3C/T and GT repeat dinucleotide microsatellite in the IFN-α/β receptor 1 (IFNAR1) gene are associated with the development of IFN-induced depression. Method: Fifty patients with chronic hepatitis C were treated with pegylated IFN α-2b plus a standard or weight-based dose of ribavirin. Severity of depression was assessed using the Zung Self-Rating Depression Scale (SDS) at baseline and at 4, 8, 12 and 24 weeks of treatment. Result: The baseline to maximum difference in the SDS index score of neurovegetative/somatic symptoms was higher in patients with the 5/14 genotype of the GT repeat dinucleotide microsatellite polymorphism than in those patients with other genotypes (p = 0.0084). Conclusion: This preliminary result suggests that the promoter GT repeat dinucleotide microsatellite polymorphism of the IFNAR1 gene may represent a risk factor for the development of depressive symptoms during IFN-α therapy for hepatitis C and other conditions.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, Kaslow RA, Margolis HS: The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999;341:556–562.
  2. Zeuzem S: What is (cost) effective in patients with chronic hepatitis C virus infection? Eur J Gastroenterol Hepatol 2001;13:473–476.
  3. Dieperink E, Willenbring M, Ho SB: Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: A review. Am J Psychiatry 2000;157:867–876.
  4. Kraus MR, Schafer A, Faller H, Csef H, Scheurlen M: Psychiatric symptoms in patients with chronic hepatitis C receiving interferon alfa-2b therapy. J Clin Psychiatry 2003;64:708–714.
  5. Loftis JM, Hauser P: The phenomenology and treatment of interferon-induced depression. J Affect Disord 2004;82:175–190.
  6. Musselman DL, Lawson DH, Gumnick JF, Manatunga AK, Penna S, Goodkin RS, Greiner K, Nemeroff CB, Miller AH: Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med 2001;344:961–966.
  7. Capuron L, Raison CL, Musselman DL, Lawson DH, Nemeroff CB, Miller AH: Association of exaggerated HPA axis response to the initial injection of interferon-alpha with development of depression during interferon-alpha therapy. Am J Psychiatry 2003;160:1342–1345.
  8. Valentine AD, Meyers CA, Kling MA, Richelson E, Hauser P: Mood and cognitive side effects of interferon-alpha therapy. Semin Oncol 1998;25:39–47.
  9. Oritani K, Kincade PW, Zhang C, Tomiyama Y, Matsuzawa Y: Type I interferons and limitin: a comparison of structures, receptors, and functions. Cytokine Growth Factor Rev 2001;12:337–348.
  10. Muldoon J, Uriel A, Khoo S, Ollier WE, Hajeer AH: Novel IFN-alpha receptor promoter polymorphisms. Genes Immun 2001;2:159–160.
  11. Matsuyama N, Mishiro S, Sugimoto M, Furuichi Y, Hashimoto M, Hijikata M, Ohta Y: The dinucleotide microsatellite polymorphism of the IFNAR1 gene promoter correlates with responsiveness of hepatitis C patients to interferon. Hepatol Res 2003;25:221–225.
  12. Raison CL, Borisov AS, Broadwell SD, Capuron L, Woolwine BJ, Jacobson IM, Nemeroff CB, Miller AH: Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction. J Clin Psychiatry 2005;66:41–48.
  13. First MB, Spitzer RL, Gibbon M, Williams JB: Structured Clinical Interview for DSM-IV. New York, Biometric Research, New York State Psychiatric Institute, 1995.
  14. Zung WW: A self-rating depression scale. Arch Gen Psychiatry 1965;12:63–70.
  15. Capuron L, Gumnick JF, Musselman DL, Lawson DH, Reemsnyder A, Nemeroff CB, Miller AH: Neurobehavioral effects of interferon-alpha in cancer patients: Phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology 2002;26:643–652.
  16. Valentine AD, Meyers CA, Talpaz M: Treatment of neurotoxic side effects of interferon-alpha with naltrexone. Cancer Invest 1995;13:561–566.
  17. Buchner A, Faul F, Erdfelder E: G·Power: A priori, post-hoc, and Compromise Power Analyses for the Macintosh (Version 2.1.2; Computer Program). Trier, University of Trier, 1997.
  18. Schafer M, Schmidt F, Soyka M, Moller HJ, Loeschke K: Psychiatric side effects during combination treatment for chronic hepatitis C with interferon-alpha and ribavirin: Comparison of psychiatric patients, drug addicts and controls. Eur Neuropsychopharmacol 2000;10:S396–397.

    External Resources

  19. Kobak KA, Taylor LH, Dottl SL, Greist JH, Jefferson JW, Burroughs D, Mantle JM, Katzelnick DJ, Norton R, Henk HJ, Serlin RC: A computer-administered telephone interview to identify mental disorders. JAMA 1997;278:905–910.
  20. Korner-Bitensky N, Wood-Dauphinee S, Siemiatycki J, Shapiro S, Becker R: Health-related information postdischarge: Telephone versus face-to-face interviewing. Arch Phys Med Rehabil 1994;75:1287–1296.
  21. Simon GE, Revicki D, VonKorff M: Telephone assessment of depression severity. J Psychiatr Res 1993;27:247–252.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50